242 related articles for article (PubMed ID: 15284852)
81. Harmonization of molecular monitoring of CML therapy in Europe.
Müller MC; Cross NC; Erben P; Schenk T; Hanfstein B; Ernst T; Hehlmann R; Branford S; Saglio G; Hochhaus A
Leukemia; 2009 Nov; 23(11):1957-63. PubMed ID: 19710700
[TBL] [Abstract][Full Text] [Related]
82. G-CSF for imatinib-induced neutropenia.
Heim D; Ebnöther M; Meyer-Monard S; Tsakiris D; Linn M; Tichelli A; Gratwohl A
Leukemia; 2003 Apr; 17(4):805-7. PubMed ID: 12682643
[No Abstract] [Full Text] [Related]
83. Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy.
Tiribelli M; Binotto G; Calistri E; Maino E; Scaffidi L; Medeot M; Nabergoj M; Ambrosetti A; Semenzato G; Fanin R; Bonifacio M;
Am J Hematol; 2015 Jul; 90(7):E135-7. PubMed ID: 25808917
[No Abstract] [Full Text] [Related]
84. Discontinuing imatinib in chronic myeloid leukemia: don't try this at home.
Mattison R; Larson RA
Leuk Lymphoma; 2009 Jun; 50(6):868-70. PubMed ID: 19455466
[No Abstract] [Full Text] [Related]
85. Distinct predictive factors influence on achievement of early molecular response by frontline imatinib in chronic phase chronic myeloid leukemia.
Lee SE; Choi SY; Oh YJ; Kim SH; Song HY; Yoo HL; Lee MY; Chae MJ; Kang KH; Hwang HJ; Jang EJ; Kim DW
Leuk Res; 2015 Apr; 39(4):411-8. PubMed ID: 25680524
[TBL] [Abstract][Full Text] [Related]
86. Blast crisis of Philadelphia chromosome-positive chronic myeloid leukaemia carrying micro-bcr breakpoint (e19a2 and e191a).
Ohsaka A; Hoshino S; Kobayashi M; Kudo H; Kawaguchi R
Br J Haematol; 2002 Jul; 118(1):251-4. PubMed ID: 12100156
[TBL] [Abstract][Full Text] [Related]
87. Clinical and genetic studies of ETV6/ABL1-positive chronic myeloid leukaemia in blast crisis treated with imatinib mesylate.
Barbouti A; Ahlgren T; Johansson B; Höglund M; Lassen C; Turesson I; Mitelman F; Fioretos T
Br J Haematol; 2003 Jul; 122(1):85-93. PubMed ID: 12823349
[TBL] [Abstract][Full Text] [Related]
88. Is b3a2 a better prognostic variant in childhood chronic myeloid leukemia?
Malhotra KP; Sharma CB; Jain J; Grover RK
J Postgrad Med; 2010; 56(3):221-2. PubMed ID: 20739774
[No Abstract] [Full Text] [Related]
89. Bcr-abl positive blast crisis of chronic myeloid leukemia emerging in a case of metastatic colorectal cancer 3 months after completion of an 8-month course of cetuximab and irinotecan.
Buxhofer-Ausch V; Hinterberger-Fischer M; Hinterberger W
Eur J Haematol; 2006 May; 76(5):447-8. PubMed ID: 16494624
[No Abstract] [Full Text] [Related]
90. Milestones and monitoring in patients with CML treated with imatinib.
Deininger MW
Hematology Am Soc Hematol Educ Program; 2008; ():419-26. PubMed ID: 19074120
[TBL] [Abstract][Full Text] [Related]
91. hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia.
Bazeos A; Marin D; Reid AG; Gerrard G; Milojkovic D; May PC; de Lavallade H; Garland P; Rezvani K; Apperley JF; Goldman JM; Foroni L; Khorashad JS
Leukemia; 2010 Jun; 24(6):1243-5. PubMed ID: 20445576
[No Abstract] [Full Text] [Related]
92. BCR-ABL1 e6a2 transcript in chronic myeloid leukemia: biological features and molecular monitoring by droplet digital PCR.
Zagaria A; Anelli L; Coccaro N; Tota G; Casieri P; Cellamare A; Impera L; Brunetti C; Minervini A; Minervini CF; Delia M; Cumbo C; Orsini P; Specchia G; Albano F
Virchows Arch; 2015 Sep; 467(3):357-63. PubMed ID: 26149409
[TBL] [Abstract][Full Text] [Related]
93. Treatment of chronic myeloid leukemia when imatinib fails.
Hehlmann R; Jung-Munkwitz S; Saussele S
Expert Opin Pharmacother; 2011 Feb; 12(2):269-83. PubMed ID: 21226637
[TBL] [Abstract][Full Text] [Related]
94. Sudden blastic crisis and additional chromosomal abnormalities during chronic myeloid leukemia in the imatinib era.
Ali R; Ozkalemkas F; Ozkocaman V; Yakut T; Nazlioglu HO; Budak F; Pekgoz M; Korkmaz S; Karkucak M; Ozcelik T; Tunali A
Int J Clin Oncol; 2009 Dec; 14(6):545-50. PubMed ID: 19967494
[TBL] [Abstract][Full Text] [Related]
95. Durability of molecular remission in chronic myeloid leukemia patients treated with imatinib vs allogeneic stem cell transplantation.
Lange T; Bumm T; Mueller M; Otto S; Al-Ali HK; Grommisch L; Musiol S; Franke C; Krahl R; Niederwieser D; Deininger MW
Leukemia; 2005 Jul; 19(7):1262-5. PubMed ID: 15858618
[No Abstract] [Full Text] [Related]
96. Reactivation of porphyria cutanea tarda as a possible side effect of Imatinib at high dosage in chronic myeloid leukemia.
Breccia M; Latagliata R; Carmosino I; Mandelli F; Alimena G
Leukemia; 2004 Jan; 18(1):182. PubMed ID: 14574325
[No Abstract] [Full Text] [Related]
97. Thriving with chronic myeloid leukaemia.
Morris RH
Lancet; 2001 Dec; 358 Suppl():S12. PubMed ID: 11784561
[No Abstract] [Full Text] [Related]
98. Concurrent megakaryocytic and erythroid chronic myelogenous leukemia blast crisis.
Westfall DE; Zhang L; Song S; Lee S
Arch Pathol Lab Med; 2008 Jun; 132(6):1021-5. PubMed ID: 18517263
[TBL] [Abstract][Full Text] [Related]
99. Comparison of the cytogenetic and molecular analyses in the assessment of imatinib response in chronic myelocytic leukemia.
Palanduz S; Bayrak A; Sirma S; Vural B; Cefle K; Ucur A; Ozturk S; Yenerel MN; Besisik SK; Yavuz S; Diz-Kucukkaya R; Sargin D; Nalcaci M; Pekcelen Y; Ozbek U
Genet Test Mol Biomarkers; 2009 Oct; 13(5):599-602. PubMed ID: 19814615
[TBL] [Abstract][Full Text] [Related]
100. Sensitivity to the abl inhibitor STI571 in fresh leukaemic cells obtained from chronic myelogenous leukaemia patients in different stages of disease.
Gambacorti-Passerini C; Barni R; Marchesi E; Verga M; Rossi F; Rossi F; Pioltelli P; Pogliani E; Corneo GM
Br J Haematol; 2001 Mar; 112(4):972-4. PubMed ID: 11298594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
